Xenon Pharmaceuticals Inc
XENE31.290USD
+0.790+2.59%
Market hours （ET）Quotes delayed by 15 min
2.40BMarket Cap
LossP/E TTM
More Details of Xenon Pharmaceuticals Inc Company
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, the Company's lead Kv7 channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. Azetukalner is being developed for the treatment of epilepsy, including focal onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS) as well as major depressive disorder (MDD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications. It has an ongoing collaboration with Neurocrine Biosciences, Inc. to develop treatments for epilepsy.
Company Info
Ticker SymbolXENE
Company nameXenon Pharmaceuticals Inc
IPO dateOct 17, 2014
CEOMr. Ian C. Mortimer, CPA
Number of employees316
Security typeOrdinary Share
Fiscal year-endOct 17
Address3650 Gilmore Way
CityVANCOUVER
Stock exchangeNASDAQ Global Market Consolidated
CountryCanada
Postal codeV5G 4W8
Phone16044843300
Websitehttps://www.xenon-pharma.com/
Ticker SymbolXENE
IPO dateOct 17, 2014
CEOMr. Ian C. Mortimer, CPA
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Ian C. Mortimer, CPA
Mr. Ian C. Mortimer, CPA
President, Chief Executive Officer, Interim Chief Financial Officer, Director
President, Chief Executive Officer, Interim Chief Financial Officer, Director
45.60K
--
Dr. Gary Patou, M.D.
Dr. Gary Patou, M.D.
Independent Director
Independent Director
28.48K
--
Ms. Dawn A. (Graham) Svoronos
Ms. Dawn A. (Graham) Svoronos
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
25.00K
--
Mr. Steven R. (Steve) Gannon, CPA
Mr. Steven R. (Steve) Gannon, CPA
Independent Director
Independent Director
7.14K
-0.04%
Dr. Christopher Kenney, M.D.
Dr. Christopher Kenney, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Darren S. Cline
Mr. Darren S. Cline
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Patrick Machado, J.D.
Mr. Patrick Machado, J.D.
Independent Director
Independent Director
--
--
Dr. Gillian M. Cannon, Ph.D.
Dr. Gillian M. Cannon, Ph.D.
Independent Director
Independent Director
--
--
Mr. Justin Gover
Mr. Justin Gover
Independent Director
Independent Director
--
--
Ms. Andrea Marie Difabio, J.D.
Ms. Andrea Marie Difabio, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Ian C. Mortimer, CPA
Mr. Ian C. Mortimer, CPA
President, Chief Executive Officer, Interim Chief Financial Officer, Director
President, Chief Executive Officer, Interim Chief Financial Officer, Director
45.60K
--
Dr. Gary Patou, M.D.
Dr. Gary Patou, M.D.
Independent Director
Independent Director
28.48K
--
Ms. Dawn A. (Graham) Svoronos
Ms. Dawn A. (Graham) Svoronos
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
25.00K
--
Mr. Steven R. (Steve) Gannon, CPA
Mr. Steven R. (Steve) Gannon, CPA
Independent Director
Independent Director
7.14K
-0.04%
Dr. Christopher Kenney, M.D.
Dr. Christopher Kenney, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Darren S. Cline
Mr. Darren S. Cline
Chief Commercial Officer
Chief Commercial Officer
--
--
Revenue Breakdown
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
Canada
7.50M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Aug 3
Updated: Sun, Aug 3
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
8.03%
Avoro Capital Advisors LLC
7.48%
Driehaus Capital Management, LLC
5.97%
Wellington Management Company, LLP
4.94%
Janus Henderson Investors
4.33%
Other
69.25%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
8.03%
Avoro Capital Advisors LLC
7.48%
Driehaus Capital Management, LLC
5.97%
Wellington Management Company, LLP
4.94%
Janus Henderson Investors
4.33%
Other
69.25%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
46.54%
Investment Advisor
30.34%
Hedge Fund
23.10%
Private Equity
1.66%
Venture Capital
1.05%
Sovereign Wealth Fund
0.83%
Research Firm
0.77%
Pension Fund
0.56%
Bank and Trust
0.27%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
416
84.68M
110.35%
+9.65K
2025Q1
434
79.94M
104.19%
-5.23M
2024Q4
434
79.81M
104.31%
-4.80M
2024Q3
425
77.49M
102.39%
-3.82M
2024Q2
431
76.92M
102.03%
-4.12M
2024Q1
421
76.68M
101.81%
-2.76M
2023Q4
404
75.13M
102.42%
+7.65M
2023Q3
386
64.60M
99.41%
-3.93M
2023Q2
377
64.25M
101.09%
-4.03M
2023Q1
347
63.79M
101.12%
-4.16M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
6.16M
8.03%
+73.87K
+1.21%
Mar 31, 2025
Avoro Capital Advisors LLC
5.74M
7.48%
+75.00K
+1.32%
Mar 31, 2025
Driehaus Capital Management, LLC
4.58M
5.97%
+64.26K
+1.42%
Mar 31, 2025
Wellington Management Company, LLP
3.79M
4.94%
+11.59K
+0.31%
Mar 31, 2025
Janus Henderson Investors
3.33M
4.33%
+458.34K
+15.99%
Mar 31, 2025
Capital International Investors
3.09M
4.03%
+541.52K
+21.26%
Mar 31, 2025
Braidwell LP
2.71M
3.53%
-204.09K
-7.00%
Mar 31, 2025
Polar Capital LLP
2.62M
3.42%
-74.62K
-2.77%
Mar 31, 2025
Commodore Capital LP
2.33M
3.03%
-415.00K
-15.15%
Mar 31, 2025
Capital World Investors
2.22M
2.9%
-69.82K
-3.04%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Neuroscience and Healthcare ETF
4.34%
Tema Neuroscience and Mental Health ETF
1.82%
ALPS Medical Breakthroughs ETF
1.62%
Virtus LifeSci Biotech Clinical Trials ETF
0.86%
Goldman Sachs Future Health Care Equity ETF
0.61%
First Trust Multi-Manager Small Cap Opportunities ETF
0.52%
Harbor Health Care ETF
0.42%
BNY Mellon Innovators ETF
0.35%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.34%
iShares Health Innovation Active ETF
0.34%
View more
iShares Neuroscience and Healthcare ETF
Proportion4.34%
Tema Neuroscience and Mental Health ETF
Proportion1.82%
ALPS Medical Breakthroughs ETF
Proportion1.62%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.86%
Goldman Sachs Future Health Care Equity ETF
Proportion0.61%
First Trust Multi-Manager Small Cap Opportunities ETF
Proportion0.52%
Harbor Health Care ETF
Proportion0.42%
BNY Mellon Innovators ETF
Proportion0.35%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Proportion0.34%
iShares Health Innovation Active ETF
Proportion0.34%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
